Technical Analysis for ONCR - Oncorus, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Flat |
Historical ONCR trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 2.01% | |
Boomer Sell Setup | Bearish Swing Setup | -3.11% | |
Narrow Range Bar | Range Contraction | -3.11% | |
NR7 | Range Contraction | -3.11% | |
NR7-2 | Range Contraction | -3.11% | |
Inside Day | Range Contraction | -3.11% | |
Wide Bands | Range Expansion | -3.11% | |
NR7 | Range Contraction | -3.72% | |
Inside Day | Range Contraction | -3.72% | |
Wide Bands | Range Expansion | -3.72% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
10 DMA Resistance | about 3 hours ago |
Rose Above Previous Day's High | about 5 hours ago |
Rose Above 10 DMA | about 5 hours ago |
20 DMA Resistance | about 5 hours ago |
Up 5% | about 5 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Therapies For Cancer Herpes Oncolytics Biotech Brain Cancer Herpes Simplex Herpes Simplex Virus Pelareorep Oncolytic Virus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Therapies For Cancer Herpes Oncolytics Biotech Brain Cancer Herpes Simplex Herpes Simplex Virus Pelareorep Oncolytic Virus
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 37.8603 |
52 Week Low | 11.5 |
Average Volume | 203,980 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 16.77 |
20-Day Moving Average | 14.31 |
10-Day Moving Average | 13.71 |
Average True Range | 1.18 |
ADX | 31.13 |
+DI | 15.76 |
-DI | 25.68 |
Chandelier Exit (Long, 3 ATRs ) | 13.70 |
Chandelier Exit (Short, 3 ATRs ) | 15.05 |
Upper Bollinger Band | 16.93 |
Lower Bollinger Band | 11.70 |
Percent B (%b) | 0.33 |
BandWidth | 36.52 |
MACD Line | -0.85 |
MACD Signal Line | -1.11 |
MACD Histogram | 0.2523 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 14.88 | ||||
Resistance 3 (R3) | 14.99 | 14.62 | 14.64 | ||
Resistance 2 (R2) | 14.62 | 14.25 | 14.56 | 14.56 | |
Resistance 1 (R1) | 14.03 | 14.03 | 13.85 | 13.93 | 14.48 |
Pivot Point | 13.66 | 13.66 | 13.57 | 13.61 | 13.66 |
Support 1 (S1) | 13.08 | 13.30 | 12.89 | 12.97 | 12.42 |
Support 2 (S2) | 12.71 | 13.07 | 12.65 | 12.34 | |
Support 3 (S3) | 12.12 | 12.71 | 12.26 | ||
Support 4 (S4) | 12.02 |